Multipotent mesenchymal stromal cells for autoimmune diseases

Transfusion Medicine and Hemotherapy

Volumn 35, Issue 4, 2008, Pages 313-318

  Tyndall, Alan ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Autoimmune disease; Mesenchymal; MSC; Stem cell; Stromal

Indexed keywords

CYCLOSPORIN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE TOXICITY; ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL EXPANSION; CELL FATE; COLITIS; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LUPUS ERYTHEMATOSUS NEPHRITIS; MESENCHYMAL STEM CELL; MULTIPLE SCLEROSIS; MULTIPOTENT STEM CELL; NONHUMAN; PATIENT SELECTION; REVIEW; SAFETY; STEM CELL TRANSPLANTATION; STREPTOZOCIN DIABETES; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTEMIC VASCULITIS;

EID: 58549110241     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000140859     Document Type: Review

References (68)

1. Javazon EH, Beggs KJ, Flake AW: Mesenchymal stem cells: paradoxes of passaging. Exp Hematol 2004;32:414-25.
2. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP: Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968;6:230-47.
3. Haynesworth SE, Goshima J, Goldberg VM, Caplan AI: Characterization of cells with osteogenic potential from human marrow. Bone 1992;13:81-8.
4. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-4.
5. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al: Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
6. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, et al: Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974;2:83-92.
7. Nakahara H, Dennis JE, Bruder SP, Haynesworth SE, Lennon DP, Caplan AI: In vitro differentiation of bone and hypertrophic cartilage from periosteal-derived cells. Exp Cell Res 1991;195:492-503.
8. Sampath TK, Nathanson MA, Reddi AH: In vitro transformation of mesenchymal cells derived from embryonic muscle into cartilage in response to extracellular matrix components of bone. Proc Natl Acad Sci U S A 1984;81:3419-23.
9. Jones EA, Kinsey SE, English A, Jones RA, Straszynski L, Meredith DM, et al: Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 2002;46:3349-60.
10. Bieback K, Kluter H: Mesenchymal stromal cells from umbilical cord blood. Curr Stem Cell Res Ther 2007;2:310-23.
11. Soncini M, Vertua E, Gibelli L, Zorzi F, Denegri M, Albertini A, et al: Isolation and characterization of mesenchymal cells from human fetal membranes. J Tissue Eng Regen Med 2007;1:296-305.
12. Horwitz E, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini F, et al: Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005;7:393-5.
13. Tyndall A, LeBlanc K: Stem cells and rheumatology: update on adult stem cell therapy in autoimmune diseases. Arthritis Rheum 2006;55:521-5.
14. Le Blanc K: Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003;5:485-9.
15. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE: Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006;108:2114-20.
16. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J: Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 2005;106:4057-65.
17. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC: Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003;75:389-97.
18. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O: Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57:11-20.
19. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838-43.
20. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, et al: T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005;12:47-57.
21. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al: Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722-9.
22. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42-8.
23. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al: Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107:367-72.
24. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F: Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005;105:2821-7.
25. Rasmusson I, Ringden O, Sundberg B, LeBlanc K: Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76:1208-13.
26. Traggiai E, Volpi S, Schena F, Gattorno M, Ferlito F, Moretta L, et al: Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008;26:562-9.
27. Tang KC, Trzaska KA, Smirnov SV, Kotenko SV, Schwander SK, Ellner JJ, et al: Down-regulation of MHC II in mesenchymal stem cells at high IFN-gamma can be partly explained by cytoplasmic retention of CIITA. J Immunol 2008;180:1826-33.
28. Plumas J, Chaperot L, Richard MJ, Molens JP, Bensa JC, Favrot MC: Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005;19:1597-604.
29. Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, et al: Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 2008;26:151-62.
30. Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-22.
31. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D: Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-21.
32. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al: Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007;109:228-34.
33. Nasef A, Mathieu N, Chapel A, Frick J, Francois S, Mazurier C, et al: Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007;84:231-7.
34. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, et al: Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 2007;104:11002-7.
35. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI: The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001;169:12-20.
36. Wynn RF, Hart CA, Corradi-Perini C, O'Neill L, Evans CA, Wraith JE, et al: A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004;104:2643-5.
37. Fox JM, Chamberlain G, Ashton BA, Middleton J: Recent advances into the understanding of mesenchymal stem cell trafficking. Br J Haematol 2007;137:491-502.
38. Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, et al: Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008;14:181-7.
39. Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, et al: Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res. 2007;13:5020-7.
40. Mouiseddine M, Francois S, Semont A, Sache A, Allenet B, Mathieu N, et al: Human mesenchymal stem cells home specifically to radiation-injured tissues in a non-obese diabetes/severe combined immunodeficiency mouse model. Br J Radiol 2007;80(spec no 1):S49-55.
41. Caplan AI, Dennis JE: Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006;98:1076-84.
42. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, et al: Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003;100:8407-11.
43. Fang B, Shi M, Liao L, Yang S, Liu Y, Zhao RC: Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation 2004;78:83-8.
44. Parekkadan B, van Poll D, Suganuma K, Carter EA, Berthiaume F, Tilles AW, et al: Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS ONE 2007;2:e941.
45. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C, et al: Amelioration of acute renal failure by stem cell therapy - paracrine secretion versus transdifferentiation into resident cells: administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation independent mechanisms. Am J Physiol Renal Physiol 2005;289:F31-42.
46. Togel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C: Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007;292:F1626-35.
47. Zhang J, Li Y, Chen J, Cui Y, Lu M, Elias SB, et al: Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 2005;195:16-26.
48. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, et al: Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106:1755-61.
49. Van Eden W, Wick G, Albani S, Cohen I: Stress, heat shock proteins, and autoimmunity: how immune responses to heat shock proteins are to be used for the control of chronic inflammatory diseases. Ann N Y Acad Sci 2007;1113:217-37.
50. Djouad F, Fritz V, Apparailly F, Louis-Plence P, Bony C, Sany J, et al: Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005;52:1595-603.
51. Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G: Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007;56:1175-86.
52. Urban VS, Kiss J, Kovacs J, Gocza E, Vas V, Monostori E, et al: Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 2008;26:244-53.
53. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI: Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995;16:557-64.
54. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, et al: Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005;11:389-98.
55. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W: Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002;30:215-22.
56. Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, et al: Rapid hematopoietic recovery after coinfusion of autologousblood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000;18:307-16.
57. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, et al: Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002;99:8932-7.
58. Fouillard L, Bensidhoum M, Bories D, Bonte H, Lopez M, Moseley AM, et al: Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma. Leukemia 2003;17:474-6.
59. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-41.
60. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579-86.
61. Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, et al: Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford) 2007;46:403-8.
62. Larghero J, Farge D, Braccini A, Lecourt S, Scherberich A, Fois E, et al: Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from systemic sclerosis patients. Ann Rheum Dis 2008;67:443-9.
63. Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A, et al: Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 2007;56:1994-2004.
64. Ball SG, Shuttleworth CA, Kielty CM: Mesenchymal stem cells and neovascularization: role of platelet-derived growth factor receptors. J Cell Mol Med 2007;11:1012-30.
65. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al: Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102:3837-44.
66. Taupin P: OTI-010 Osiris Therapeutics/JCR Pharmaceuticals. Curr Opin Investig Drugs 2006;7:473-81.
67. Le Blanc K, Fibbe W: A new cell therapy registry coordinated by the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2008;41:319.
68. Tyndall A, Walker U, Cope A, Dazzi F, De Bari C, Fibbe W, et al: Immunomodulatory properties of mesenchymal stem cells - a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther 2007;9:301.